Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHuan WangFLFei Li

Discussion

Loading...

Member takes

Overview

Observational analysis reveals KPNA2 influences drug resistance in multiple myeloma, indicating its role as a prognostic biomarker.

Key Points

  • Elevated KPNA2 expression promotes autophagy and drug resistance in multiple myeloma cells, highlighting its critical role.
  • Quantitative analysis indicated that multiple myeloma patients showed significantly increased KPNA2 compared to healthy donors, correlating with poor survival.
  • Investigation through transcriptomic profiling reveals pathways related to KPNA2 influence on cell behaviors like invasion and cytotoxicity.
  • Therapeutic targeting of KPNA2 may enhance responses to treatments, suggesting potential pathways to overcome drug resistance.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4bfhttps://doi.org/10.1182/blood-2025-7478
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integration of autophagy-related genes and immune dysregulation reveals a prognostic landscape in multiple myeloma2025
  2. 2Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma2025
  3. 3Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma2025 · 1 citations
  4. 4Oncogenic ASPP2κ: A novel regulator of drug resistance and tumor progression in multiple myeloma2025
  5. 5Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma2025 · 1 citations